|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/40 | |
| A61K 9/22 | |||
| A61K 9/24 |
| (11) | Number of the document | 2191824 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09172285.0 |
| Date of filing the European patent application | 2006-06-08 | |
| (97) | Date of publication of the European application | 2010-06-02 |
| (45) | Date of publication and mention of the grant of the patent | 2012-03-14 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 689719 P | 2005-06-10 | US | |
| 690309 P | 2005-06-14 | US |
| (72) |
Kowalski, James, US
Lakshman, Jay, Parthiban, US
Serajuddin, Abu, T. M., US
Joshi, Yatindra, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Novartis Pharma GmbH, Brunner Strasse 59, 1230 Wien, AT |
| (54) | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |